About: Implications of AB0 blood group in hypertensive patients with covid-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Implications of AB0 blood group in hypertensive patients with covid-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Implications of AB0 blood group in hypertensive patients with covid-19
Creator	Cirillo, Paolo Codella, Vinicio Gambardella, Jessica Gatta, Gianluca Maggi, Paolo Marfella, Raffaele Messina, Vincenzo Paolisso, Giuseppe Santulli, Gaetano Sardu, Antonio Sardu, Celestino
Source	Medline; PMC
abstract	BACKGROUND: Hypertension is the most frequent co-morbidity in patients with covid-19 infection, and we might speculate that a specific blood group could play a key role in the clinical outcome of hypertensive patients with covid-19. METHODS: In this prospective study, we compared 0 vs. non-0 blood group in hypertensive patients with covid-19 infection. In these patients, we evaluated inflammatory and thrombotic status, cardiac injury, and death events. RESULTS: Patients in non-0 (n = 92) vs. 0 blood group (n = 72) had significantly different values of activated pro-thrombin time, D-dimer, and thrombotic indexes as Von Willebrand factor and Factor VIII (p < 0.05). Furthermore, patients in non-0 vs. 0 blood group had higher rate of cardiac injury (10 (13.9%) vs. 27 (29.3%)) and death, (6 (8.3%) vs. 18 (19.6%)), (p < 0.05). At the multivariate analysis, Interleukin-6 (1.118, CI 95% 1.067–1.171) and non-0 blood group (2.574, CI 95% 1.207–5.490) were independent predictors of cardiac injury in hypertensive patients with covid-19. D-dimer (1.082, CI 95% 1.027–1.140), Interleukin-6 (1.216, CI 95% 1.082–1.367) and non-0 blood group (3.706, CI 95% 1.223–11.235) were independent predictors of deaths events in hypertensive patients with covid-19. CONCLUSIONS: Taken together, our data indicate that non-0 covid-19 hypertensive patients have significantly higher values of pro-thrombotic indexes, as well as higher rate of cardiac injury and deaths compared to 0 patients. Moreover, AB0 blood type influences worse prognosis in hypertensive patients with covid-19 infection.
has issue date	2020-08-14(xsd:dateTime)
bibo:doi	10.1186/s12872-020-01658-z
bibo:pmid	32799852
has license	cc-by
sha1sum (hex)	559f220d8c4dc5d3cc577504442a58ea5740ad21
schema:url	https://doi.org/10.1186/s12872-020-01658-z
resource representing a document's title	Implications of AB0 blood group in hypertensive patients with covid-19
has PubMed Central identifier	PMC7427694
has PubMed identifier	32799852
schema:publication	BMC Cardiovasc Disord
resource representing a document's body	covid:559f220d8c4dc5d3cc577504442a58ea5740ad21#body_text
is schema:about of	named entity 'influences' named entity 'events' named entity 'prognosis' named entity 'Hypertension' named entity 'patients' named entity '118' named entity 'VON WILLEBRAND FACTOR' named entity 'D-dimer' named entity 'blood group' named entity 'data' named entity 'speculate' named entity 'compared' named entity 'blood group' named entity 'co-morbidity' named entity 'inflammatory' named entity 'multivariate analysis' named entity 'Results' named entity 'hypertensive' named entity 'Von Willebrand factor' named entity 'blood type' named entity 'Von Willebrand factor' named entity 'Hypertension' named entity 'hypertensive' named entity 'blood group' named entity 'clinical outcome' named entity 'covid-19' named entity 'covid-19' named entity 'Interleukin-6' named entity '95%' named entity 'activated prothrombin time' named entity 'thrombotic' named entity 'infection' named entity 'blood group' named entity 'D-dimer' named entity 'CABG' named entity 'blood group' named entity 'blood group' named entity 'ACE2' named entity 'covid-19' named entity 'electrolytes' named entity 'inflammation' named entity 'D-dimer' named entity 'respiratory tract' named entity 'blood group' named entity 'survival analysis' named entity 'covid-19' named entity 'cardiovascular complications' named entity 'inflammation' named entity 'covid-19' named entity 'oxygen therapy' named entity 'A297' named entity 'covid-19' named entity 'inflammation' named entity 'respiratory failure' named entity 'covid-19' named entity 'respiratory failure' named entity 'echocardiography' named entity 'thromboembolism' named entity 'coronary artery bypass grafting' named entity 'interleukin-6' named entity 'blood groups' named entity 'hydroxychloroquine' named entity 'Luigi Vanvitelli' named entity 'upper airways' named entity 'reverse transcription' named entity 'covid-19' named entity 'MALDI-TOF' named entity 'covid-19' named entity 'troponin' named entity 'coagulopathy' named entity 'Italy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software